A biomarker for fast progressors in glaucoma?

INTERVENTION: Continued treatment group: Participants will continue to receive the same treatment started before recruitment. Participants reaching any of the end‐points, including VF progression, decrease in VA greater than or equal to 2 lines, and IOP greater than 30mmHg on 2 consecutive follow‐up visits in anytime during the study period will be excluded from the study and receive additional treatment, which is the same as the additional IOP lowering treatment group. Only the investigator (ophthalmologist)will deliver the intervention. CONDITION: Glaucoma PRIMARY OUTCOME: Use of two Visual Field tests, separated by at least 30 min., will be performed for each eye at the baseline visit. ; ; Outcome would be "Proportion of eyes with VF progression ". SECONDARY OUTCOME: Proportion of eyes with RNFL progression ; ; Use of SDOCT imaging to assess Rate of change of LC deformation before and after IOP reduction ; ; Use of visual fields results and. SDOCT imaging and corneal hysteresis (Ocular Response Analyzer), and other biometric and ocular variables (e.g. axial length and ocular perfusion pressure) Rate of change visual field index ; ; Use of visual field tests to assess INCLUSION CRITERIA: 1.Age 18 years or older 2.Best corrected visual acuity greater than or equal to 20/40 3.POAG patients diagnosed within 12 months without prior history of glaucoma surgical/laser procedure and receiving not more than one topical IOP lowering medication and have been followed up at least 36 months in ongoing study named as “Diagnostic Imaging Assessment in the Evaluation of Glaucomatous Optic Neuropathy and diagnosed with glaucoma “at Hong Kong Eye Hospital'.